Search

A study conducted at Khyber Teaching Hospital compared the efficacy of sublingual versus vaginal misoprostol for treating first-trimester missed miscarriages. The research found that the sublingual approach had a higher success rate and was associated with fewer adverse effects compared to the vaginal method. Patients reported feeling more comfortable with the sublingual administration, indicating a preference for this method. The study concluded that sublingual misoprostol was more effective and better tolerated by patients. [Extracted from the article]

Researchers at Galgotias University in Greater Noida, India, have highlighted the recent advancements in drug delivery systems, specifically focusing on 3D printable customized drug delivery systems for vaginal therapeutics. These systems offer personalized designs and the ability to integrate multiple functional substances, potentially enhancing the efficacy of vaginal drug delivery. While significant progress has been made in manufacturing processes, challenges such as cost-effectiveness, scalability, and regulatory compliance remain. The study emphasizes the need to overcome these challenges and explores the potential of 3D printing technology in shaping the future of drug administration systems. [Extracted from the article]

A study conducted by Hasanuddin University in Makassar, Indonesia, has explored the use of efavirenz (EFV) as an antiretroviral treatment for HIV. The research focused on improving the solubility and delivery of EFV through the use of an inclusion complex (IC) and dissolving microneedles (DMN). Spectrophotometric and colorimetric methods were validated to determine the amount of EFV in various biological matrices. The study found that the IC-EFV incorporation and DMN platform showed promising results in terms of release, penetration, drug retention, and bioavailability. The research has been peer-reviewed and provides valuable insights into the development of EFV-based treatments for HIV. [Extracted from the article]

A patent has been issued to Evofem Inc. for compositions and methods that enhance the efficacy of contraceptive microbicides. The patent addresses the need for dual-purpose contraceptive microbicides that can prevent the transmission of sexually transmitted diseases (STDs), including HIV and HSV-2, while also preventing unwanted pregnancies. The compositions described in the patent include bioadhesive compounds, lactic acid, and a matrix-forming compound, among other ingredients. These compositions aim to provide improved contraceptive and microbicidal activity without causing irritation or toxicity. The patent also discusses the limitations of currently available vaginal contraceptive formulations and the need for more effective options. [Extracted from the article]

A patent application has been submitted for the development of methods, compositions, and devices related to vaginal microbiota. The invention aims to provide therapeutic compositions for vaginal diseases and adverse health conditions in women. The compositions primarily consist of Lactobacillus species and effectively treat inflammation in the female genitourinary tract. The patent application also includes information on dosage forms and methods of administration for these compositions. The methods for producing the compositions involve obtaining a microbiota sample from a donor and conducting tests and screenings to ensure safety and viability. [Extracted from the article]

This document provides information about a clinical study on the long-term effectiveness and immuno-persistence of a bivalent human papillomavirus (HPV) vaccine. The study aims to evaluate the vaccine's protective efficacy against future HPV infections and related diseases in girls aged 9-17 years. It will also investigate the persistence of vaccine-induced antibodies and the potential for type replacement/competition phenomena post-vaccination. The study is being conducted in China by Xiamen University in collaboration with Xiamen Innovax Biotech Co., Ltd and the Center for Disease Control and Prevention. The estimated enrollment is 2188, and the study is expected to be completed by December 31, 2026. [Extracted from the article]

A patent application has been submitted for a new drug delivery system that aims to provide a more effective and less side-effect prone method of contraception. The system involves a core containing a combination of estrogen and progestin compounds, which is covered by a membrane. When placed in the vaginal tract, the system releases a low dose of these compounds over time to prevent pregnancy. The patent application also includes details on methods for contraception and manufacturing the drug delivery system. [Extracted from the article]

A recent study conducted by researchers at Queen's University Belfast explores the development of 3D-printed vaginal devices containing metronidazole as an alternative treatment for bacterial vaginosis (BV). BV is an abnormal condition caused by changes in the vaginal microbiota, with Gardnerella vaginalis being one of the most common bacteria associated with BV. The study proposes the use of biodegradable and biocompatible polymers to create intravaginal devices that provide prolonged delivery of metronidazole. The devices were able to sustain the release of metronidazole for up to 9 days and exhibited antimicrobial properties against Gardnerella vaginalis. These findings suggest that the 3D-printed vaginal devices could offer a valuable alternative to current BV treatments by reducing the frequency of administration and improving patient compliance. [Extracted from the article]

A recent study conducted by researchers at Shandong University in China compared the effectiveness of oral micronized progesterone and vaginal progesterone gel as luteal phase support in fresh embryo transfer cycles. The study found that the ongoing pregnancy rate in the group administered oral micronized progesterone was non-inferior to that in the group administered vaginal progesterone gel. The researchers concluded that oral micronized progesterone may be a viable alternative for patients who are reluctant to use the vaginal route of administration. However, further investigation is needed to determine the effects of higher doses of oral micronized progesterone. The study was funded by the National Natural Science Foundation of China and was published in the journal Human Reproduction. [Extracted from the article]

Keywords: Bacterial Infections and Mycoses; Clinical Research; Clinical Trial Identifier NCT06069531; Clinical Trials and Studies; Genetics; Gram-Positive Asporogenous Rods; Gram-Positive Bacteria; Gram-Positive Rods; Gynecology; Health and Medicine; Inflammation; Lactobacillaceae; Lactobacillales; Lactobacillus; Software; Women's Health EN Bacterial Infections and Mycoses Clinical Research Clinical Trial Identifier NCT06069531 Clinical Trials and Studies Genetics Gram-Positive Asporogenous Rods Gram-Positive Bacteria Gram-Positive Rods Gynecology Health and Medicine Inflammation Lactobacillaceae Lactobacillales Lactobacillus Software Women's Health 748 748 1 10/24/23 20231023 NES 231023 2023 OCT 23 (NewsRx) -- By a News Reporter-Staff News Editor at Women's Health Weekly -- Staff editors report on the newly launched clinical trial, NCT06069531, which has the following summary description: "The goal of this clinical trial is to explore the effect of Lactobacillus johnsonii and white pomegranate extract on female bacterial status, it aims to answer are: Evaluate Lactobacillus johnsonii TCI250 probiotics or white pomegranate extract in regulating female vaginal bacteria and improving vaginal health. Evaluate Lactobacillus johnsonii TCI250 probiotics or white pomegranate extract in regulating inflammation. Exclusion Criteria (1) Pregnant or lactating women (2) Antibiotic usage (3) Other reproductive-related inflammatory diseases (e.g., candidiasis, gonorrhea, chlamydia infection) (4) Allergy to probiotics or White Pomegranate-related components iii. [Extracted from the article]

Keywords: Shanghai; People's Republic of China; Asia; Brachytherapy; Cancer; Cervical Cancer; Drugs and Therapies; Health and Medicine; Oncology; Radiotherapy; Therapy; Women's Health EN Shanghai People's Republic of China Asia Brachytherapy Cancer Cervical Cancer Drugs and Therapies Health and Medicine Oncology Radiotherapy Therapy Women's Health 1028 1028 1 09/19/23 20230922 NES 230922 2023 SEP 19 (NewsRx) -- By a News Reporter-Staff News Editor at Women's Health Weekly -- Current study results on Oncology - Cervical Cancer have been published. For more information on this research see: Application of Portable Vaginal Irrigator In Patients With Cervical Cancer Undergoing External Irradiation Combined With Intracavitary Brachytherapy. [Extracted from the article]

Keywords: Acquired Immunodeficiency Syndrome; Antimicrobials; Chemicals; Drugs and Therapies; HIV/AIDS; Health and Medicine; Hydrogen Peroxide; Immune System Diseases and Conditions; Immunization and Public Health; Microbicides; Nonoxynol 9 Therapy; Patent Application; Pharmaceuticals; Primate Lentiviruses; RNA Viruses; Retroviridae; Risk and Prevention; Vaccination; Vaccines; Vertebrate Viruses; Viral Sexually Transmitted Diseases and Conditions; Virology; Women's Health EN Acquired Immunodeficiency Syndrome Antimicrobials Chemicals Drugs and Therapies HIV/AIDS Health and Medicine Hydrogen Peroxide Immune System Diseases and Conditions Immunization and Public Health Microbicides Nonoxynol 9 Therapy Patent Application Pharmaceuticals Primate Lentiviruses RNA Viruses Retroviridae Risk and Prevention Vaccination Vaccines Vertebrate Viruses Viral Sexually Transmitted Diseases and Conditions Virology Women's Health 132 132 1 08/21/23 20230825 NES 230825 2023 AUG 21 (NewsRx) -- By a News Reporter-Staff News Editor at Vaccine Weekly -- A patent application by the inventor GUTHRIE, Wendell (San Diego, CA, US), filed on August 29, 2022, was made available online on August 3, 2023, according to news reporting originating from Washington, D.C., by NewsRx correspondents. Rapid drug clearance and the toxicity of parent compounds or metabolites also constitute some of the major drawbacks that may slow down the development and use of many antiviral agents. Worldwide, the heterosexual transmission of AIDS is the prevalent mode of transmission of AIDS, accounting for about 90% of all HIV infections in women. [Extracted from the article]

Contraception, Contraceptives, Drugs and Therapies, Estradiol Congeners, Alkylated Estrogenic Steroids, Estradiol Therapy, Estrogens, Ethinyl Estradiol Therapy, Gonadal Steroid Hormones, Gonadal Hormones, Health and Medicine, Hormone Replacement Therapy, Pharmaceuticals, Reproductive Medicine, Sex Hormones, Reproductive Techniques, Vaginal Preparations, Vaginal Agents Keywords: Alkylated Estrogenic Steroids; Contraception; Contraceptives; Drugs and Therapies; Estradiol Congeners; Estradiol Therapy; Estrogens; Ethinyl Estradiol Therapy; Gonadal Hormones; Gonadal Steroid Hormones; Health and Medicine; Hormone Replacement Therapy; Pharmaceuticals; Reproductive Medicine; Reproductive Techniques; Sex Hormones; Vaginal Agents; Vaginal Preparations EN Alkylated Estrogenic Steroids Contraception Contraceptives Drugs and Therapies Estradiol Congeners Estradiol Therapy Estrogens Ethinyl Estradiol Therapy Gonadal Hormones Gonadal Steroid Hormones Health and Medicine Hormone Replacement Therapy Pharmaceuticals Reproductive Medicine Reproductive Techniques Sex Hormones Vaginal Agents Vaginal Preparations 497 497 1 07/31/23 20230804 NES 230804 2023 AUG 4 (NewsRx) -- By a News Reporter-Staff News Editor at Drug Week -- Researchers detail new data in ethinyl estradiol therapy. [Extracted from the article]

Keywords: Clinical Research; Clinical Trials and Studies; Drugs and Therapies; Genitourinary Tract Agents; Health and Medicine; Hormones; Hyponatremia; Metabolic Diseases and Conditions; Neurologic Manifestations; Nutritional and Metabolic Diseases and Conditions; Nutritional and Metabolic Diseases and Conditions - Hyponatremia; Oxytocin Therapy; Pain; Pharmaceuticals; Pharmacodynamics; Pharmacokinetics; Pharmacology; Risk and Prevention; Uterotonic Agents; Water-Electrolyte Imbalance EN Clinical Research Clinical Trials and Studies Drugs and Therapies Genitourinary Tract Agents Health and Medicine Hormones Hyponatremia Metabolic Diseases and Conditions Neurologic Manifestations Nutritional and Metabolic Diseases and Conditions Nutritional and Metabolic Diseases and Conditions - Hyponatremia Oxytocin Therapy Pain Pharmaceuticals Pharmacodynamics Pharmacokinetics Pharmacology Risk and Prevention Uterotonic Agents Water-Electrolyte Imbalance 420 420 1 07/17/23 20230717 NES 230717 2023 JUL 17 (NewsRx) -- By a News Reporter-Staff News Editor at Clinical Trials Week -- Staff editors report on the newly launched clinical trial, NCT05929339, which has the following summary description: "The goal of this clinical trial is to learn about oxytocin (a naturally occurring hormone made in the brain that transmits messages) and the effects it may have on thermal heat pain after intravenous administration. Pain will be determined using a Verbal Pain scale 0-10. 0 is equivalent to NO PAIN and 10 is equivalent to THE WORST PAIN IMAGINABLE. [Extracted from the article]

All patients will undergo an artificial cycle frozen embryo transfer (AC-FET) with transdermal estradiol 6mg/day Patients undergoing an artificial cycle FET will start estrogen priming with transdermal estradiol 6mg/day (Estrogel(R)) on cycle D1-D3. All patients will undergo an artificial cycle frozen embryo transfer (AC-FET) with transdermal estradiol 6mg/day Patients undergoing an artificial cycle FET will start estrogen priming with transdermal estradiol 6mg/day (Estrogel(R)) on cycle D1-D3. [Extracted from the article]

Our news editors obtained a quote from the research from American Hospital: "Methods:This observational, assessor-blind study was conducted in the Women's Health Clinic of the American Hospital from 2015 to 2017. Keywords: Gynecology; Health and Medicine; Women's Health EN Gynecology Health and Medicine Women's Health 2023 MAR 2 (NewsRx) -- By a News Reporter-Staff News Editor at Women's Health Weekly -- Research findings on agriculture are discussed in a new report. [Extracted from the article]

Clindamycin gel can be prescribed to treat bacterial vaginosis in women age 12 years and older. [ABSTRACT FROM AUTHOR]

PRESCRIBING NOTES For other antifungal therapies see Section 11B. CLEOCIN VAGINAL Rx CREAM Pfizer Lincosamide. Clindamycin (as phosphate) 2%. Indications: Bacterial vaginosis. Adults: 1 applicatorful intravaginally at bedtime. Nonpregnant: treat [...]

The article discusses HIV reductions observed in women who participated in a clinical trial directed by scientist Salim Abdool Karim of a vaginal gel that contained the anti-retroviral agent tenofovir.

Reports on the possible development of an AIDS microbicide, which would prevent transmission of the disease. Failure of the microbicide non-oxynol 9; Details of the topical gel Carraguard created by the nonprofit group Population Council; Plans for clinical trials of Carraguard; Hope that the price of the gel will be low enough for people in poor countries to afford.

The article discusses study conducted by Women's Health Initiative (WHI), discussing hesitation among women treating menopausal symptoms with hormone therapy, and mentions that hormone therapy increases risks of strokes, and blood clots.

The article reviews Intrarosa, prasterone (dehydroepiandrosterone [DHEA]) vaginal insert approved by the U.S. Food and Drug Administration for treatment of dyspareunia due to menopause.

The article presents questions and answers related to women's health services that includes information related to vaginal product associated with pain reduction during an intercourse; and increment in risk over health conditions with prolonged sitting posture for reading books.

The article discusses research on vaginal microbicide for HIV infection prevention, with reference to a study by Karim Q. Abdool and colleagues in the July 19, 2010 issue of 'Science."

VAGINAL TREATMENTS DOLLAR SALE $214.3 mil. * % Change vs. Prior 12 Months Total * -4.9% Supermarkets -8.1% Drug Stores -3.7% UNIT VOLUME 18.6 mil * Total * -4.1% Supermarkets [...]

The article offers information about the oral and topical medications for treating vulvar vestibulitis (VVS) or vaginal pain. It mentions the cause of VVS which include injury, irritation and pain in the vulva nerves and bacterial infection due to human papillomavirus is the main reason for the vaginal pain. It further informs about the medications which include amitriptyline, anti-seizure drug gabapentin (Neurontin) and pamelor.

The article provides an answer to a question of whether vaginal estrogens used for vaginal dryness have the same risks as estrogens taken orally or by skin patch.

The article discusses research coauthored by scientists Salim Abdool Karim and Quarraisha Abdool Karim on the use of a vaginal gel containing the drug tenofovir to protect women from HIV infections. The study of 889 sexually active women indicated more than a 50 percent reduction in HIV infection among gel users. The gel is said to be applicable for use in Africa and other countries where condom use may be difficult to negotiate.

The article reports on the study led by Rajendra B. Nerli of the Department of Urology, KLES Kidney Foundation in India indicating that transobturator vaginal tape (TOT) is safer and as effective as tension-free vaginal tape (TVT) in treating women with stress urinary incontinence (SUI). Due to perioperative complications of TVT, TOT have been developed in which sling materials are drawn in the obturator foramina. It mentions that 88.6% of 36 women with SUI were cured after 12 months.

The article presents a case report of cardiac decompensation following intrauterine administration. After undergoing caesarean section, a girl developed cardiac decompensation after receiving intrauterine methylergometrine for persistent uterine atony. The girl started getting an infusion of dobutamine and her motion abnormalities resolved almost immediately. The author's comment is provided.

Presents a study which focused on the impact of taking arimidex and tamoxifen with replens vaginal moisturizer on the quality of life of breast cancer patients undergoing treatment with aromatase inhibitors. Background of the study.

Presents drug research briefs as of July 2004. Bioequivalence of lansoprazole orally disintegrating tablets when administered intact or dispersed in water based from a study by D. A. Gremse and colleagues published in the June 2004 issue of "Alimentary Pharmacology and Therapeutics"; Preferential distribution of estradiol tablets to the uterus through its placement in the upper third of the vagina referencing a study by E. Cicinelli and colleagues published in the May 2004 issue of "Fertility and Sterility."

Presents medication-related news briefs as of July 10, 2004. Ability of Remoxy to be less abusable than Oxycontin; Advantages of the vaginal administration of misoprostol as compared to oral or rectal drug administration.

Discourages vaginal administration of Efudex (5-fluororacil) after loop electrosurgical excision procedure for cervical intraepithelial neoplasia due to adverse symptoms and the removal of premalignant lesion.